You are here

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Statin therapy now more common than steroids in clinical practice’ by Pareek and Chankurdar
Free
  1. Gulsen Ozen1,2,
  2. Sofia Pedro3,
  3. Kaleb Michaud1,3
  1. 1 Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
  2. 2 Faculty of Medicine, Marmara University, Istanbul, Turkey
  3. 3 National Data Bank for Rheumatic Diseases, Wichita, Kansas, USA
  1. Correspondence to Dr Kaleb Michaud, Department of Medicine, University of Nebraska Medical Center, Omaha, 68198–6270 NE, USA; kmichaud{at}unmc.edu

https://doi.org/10.1136/annrheumdis-2016-210906

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the interest shown by Pareek and Chankurdar1 concerning our recent study on diabetes mellitus (DM) risk associated with disease-modifying antirheumatic drugs and statins in patients with rheumatoid arthritis (RA).2 They pointed out that statin-associated DM risk in patients with RA might be a more important concern than the risk attributed to glucocorticoids (GCs) due to longer treatment durations.1

    We agree that statin treatment is potentially continued for a longer duration than GC when initiated in patients with RA, as in the case of our cohort (median (IQR) duration for statins: 13 (6–26) months vs GC: 7 (0–17) months). However, GCs are more frequently used in patients with RA than statins …

    View Full Text

    Linked Articles